Loading news...
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately.
SG Americas Securities LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,345 shares of the company's stock, valued at approximately $911,000. Other large investors have
The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
The biotech has formally submitted a biologics license application to the FDA for its kidney disease drug. It has been accepted for priority review by the healthcare industry regulator.
Vera Therapeutics Inc. (NASDAQ: VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company's atacicept Biologics License Application (BLA) for Priority Review.
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
Wells Fargo analysts believe a combination of tax refund spending, stronger earnings in lagging sectors, and fresh liquidity from the Federal Reserve could spark a “reflation” in equities. In a note led by strategist Ohsung Kwon, the investment firm said heavily shorted names in the “Russell 3000” may be particularly well-positioned for a rebound.
Vera Therapeutics, Inc. (NASDAQ: VERA - Get Free Report) Director Patrick Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the purchase, the director owned 5,882 shares of the
BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share.
BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.
BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
American Century Companies Inc. increased its stake in Vera Therapeutics, Inc. (NASDAQ: VERA) by 89.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 714,428 shares of the company's stock after buying an additional 336,978 shares during the quarter. American Century Companies
The biotech received a significant boost from a new analyst note. The prognosticator authoring it reiterated his strong buy recommendation on the stock.
An analyst expressed his very bullish view on the biotech in a new research note. He reiterated his equivalent of a buy recommendation, and his lofty price target.
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R.
BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Exploring Yale's Investment Moves in the Third Quarter of 2025 Yale University (Trades, Portfolio) recently submitted its 13F filing for the third quarter of 2